Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
Streamline your rAAV workflows with simplified lysate purification – enabling faster, more reliable analytics for upstream samples.
news

FDA rejects AstraZeneca’s Farxiga treatment

12
SHARES

AstraZeneca has been issued with a complete response letter for Farxiga by the FDA meaning that it has rejected the treatment.

The US Food and Drug Administration (FDA) has issued a complete response letter to AstraZeneca regarding the supplemental New Drug Application for Farxiga (dapagliflozin), meaning that the governing body has initially rejected the treatment.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Farxiga is an inhibitor of SGLT2 indicated as additional treatment to diet and exercise to improve glycaemic control in adults with Type II diabetes. It is not approved to reduce the risk of renal or CV death, or to slow the progression of kidney disease. 

The application of Farxiga was as an adjunct treatment to insulin to improve glycaemic control in adult patients with Type I diabetes, when insulin alone does not provide adequate glycaemic control.

This comes after data from the Phase III DECLARE-TIMI 58 trial found that the drug showed a 47 percent reduction in the composite of kidney function decline, end-stage renal disease (ESRD) or renal death.

“Heart failure and renal diseases are two of the most common and early complications experienced by people living with Type II diabetes, and are too often overlooked,” said Elisabeth Björk, senior vice president, BioPharmaceuticals R&D, said of the data. “They contribute to a growing economic burden on the global healthcare system and can lead to fatal outcomes for patients. These data continue to offer clinically relevant evidence of the early cardio-renal effects of Farxiga.”

AstraZeneca has said that it will work closely with the FDA to discuss the next steps.

Share via
Share via